ReviewJournal of translational medicine2007
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma.
Review in Journal of translational medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 96 citations in OpenAlex.
- Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.Journal of translational medicine · 2024Article
- A maternal high-fat diet induces fetal origins of NASH-HCC in mice.Scientific reports · 2022Article
- Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?World journal of hepatology · 2022Review
- Serum gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can predict the prognosis of hepatocellular carcinoma: a meta-analysis and systematic review.Translational cancer research · 2022Article
- MAEL as a diagnostic marker for the early detection of esophageal squamous cell carcinoma.Diagnostic pathology · 2021Article
- Article
- Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma.Current medical science · 2020Article
- Biomarkers for Hepatocellular Carcinoma.Biomarkers in cancer · 2017Review
- Hepatocellular carcinoma: Review of disease and tumor biomarkers.World journal of hepatology · 2016Review
- Article
- Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt.PloS one · 2014Observational
- Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma.Experimental and therapeutic medicine · 2013Article
- Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma.BMC research notes · 2012Article
- Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.Journal of hepatology · 2012Article
- Circulating tumor cells measurements in hepatocellular carcinoma.International journal of hepatology · 2012Article
- Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.The Yale journal of biology and medicine · 2011Review
- Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma.Journal of experimental & clinical cancer research : CR · 2011Article
- Serum markers of hepatocellular carcinoma.Digestive diseases and sciences · 2010Review
- Identification of a novel human cancer/testis gene MAEL that is regulated by DNA methylation.Molecular biology reports · 2010Article
- A review on laboratory liver function tests.The Pan African medical journal · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in our cellular and molecular knowledge, hepatocellular carcinoma (HCC) remains one of the major public health problems throughout the world. It is now known to be highly heterogeneous: it encompasses various pathological entities and a wide range of clinical behaviors, and is underpinned by a complex array of gene alterations that affect supra-molecular processes.Four families of HCC tumour markers have been recently proposed: a) onco-fetal and glycoprotein antigens; b) enzymes and iso-enzymes; c) cytokines and d) genes. A category of tumour-associated antigens called cancer-testis (CT) antigens has been identified and their encoding genes have been extensively investigated. CT antigens are expressed in a limited number of normal tissues as well as in malignant tumors of unrelated histological origin, including the liver. Given that cancers are being recognized as increasingly complex, we here review the role of CT antigens as liver tumour biomarkers and their validation process, and discuss why they may improve the effectiveness of screening HCC patients and help in determining the risk of developing HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.